Business Development Associate | bio-1.rutgers.edu

Business Development Associate

Contact Information
Contact Name: 
Debra Duffy
Organization Name: 
Elusys Therapeutics, Inc.
Position Location: 
25 Riverside Drive, Pine Brook, NJ, 07058
Contact Email: 
Contact Phone: 
973-808-0222

~Position Summary: This opportunity will provide the chance to gain experience and do actual work within the department. Training will be given by the Vice President of Business Development. Training will be given to enable the fellow to provide business development support within the department and will include the day-to-day activities below.

~Day-to-Day Activities:

• Data gathering:
o Internet based research targeting publicly available information on key companies (identified by Elusys) including SEC filings, analysts reports and company and industry web sites.

• Data analysis:
o Conversion of the above information into relevant, actionable business intelligence.

• Communication:
o Report writing and presentation of business intelligence to senior executives at Elusys.

~Training Outcomes: The fellow will gain experience and skills in the areas described in the day-to-day activities.

~Field of Study Related to Position: Biotechnology.

~Minimum Educational Requirements: Bachelor's.

~Number of Positions Available: 1.

~Fellow Position will be unpaid.

~Minimum Hours per Week: 20+ hours/week.

~How to Apply: Please send resume with a cover letter to: Debra Duffy, Director of Administration: dduffy@elusys.com. In the Subject Field of the email, please write: "Applying to Bio-1 Fellowship: Business Development Associate Position."

***All successful fellows should plan to be available on Monday, October 26th, 2009 from 4 p.m. to 7 p.m. for the Bio-1 Fellowship Kickoff Event. Details will be provided to fellows.***

Additional Job or Internship Information
Position Type: 
Fellowship
Number of Openings: 
1
Length in Months: 
3
Paid: 
No
Organization Profile: 
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, therapeutic antibody, Anthim™, for the treatment of anthrax infection following a biowarfare attack. Anthim has completed a phase I safety study and is a leading candidate for purchase by the US government.